Express Pharma

Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData

In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the pivotal Phase III MAESTRO-NASH clinical trial

0 212